The 310-fold number: GLP-1 prescribing in children under 12
On September 4 researchers at NYU Langone Health published a number that is easy to misread in both directions. Among more than 3.5 million American children aged eight to eleven who had obesity but not diabetes, 20,282 were prescribed a GLP-1 receptor agonist. The share receiving one rose from 0.03 percent in 2019 to 9.3 percent by June 2026, roughly a 310-fold increase in seven years. The medicine prescribed most often was Wegovy, Novo Nordisk's semaglutide. Read one way, this is still a small minority of children. Read the other way, it is the steepest adoption curve this field has produced in any age group.
The composition of that group matters more than the headline percentage, and it is the part most coverage skipped. Ninety-four percent of the treated children had severe obesity, not ordinary excess weight. About sixty-five percent already had at least one related condition: high cholesterol, high blood pressure, sleep apnoea. These are not children being medicated toward a thinner school photograph. They are, by the study's own description, the sickest end of a paediatric population that until recently had almost nothing on offer beyond diet advice that rarely worked. Any argument about whether this prescribing is appropriate has to start there, because the alternative was not a healthier child. It was usually nothing.
Here is where it gets complicated. These medicines are not approved in the United States for children under twelve; Wegovy's paediatric approval begins at twelve. What allows the prescriptions is that clinical guidelines permit obesity pharmacotherapy from age eight in selected cases, and a doctor may prescribe outside a label when they judge it warranted. So this is off-label use, but it is not rogue use. It sits in the gap between what a guideline endorses and what a regulator has reviewed. That gap is legal and common across paediatrics. It also means nobody had to submit a dossier of paediatric evidence to anyone before this became a nine percent phenomenon.
For an investor the reading cuts both ways, and both directions are real. Demand below the age of twelve has now been demonstrated at scale without a single marketing dollar aimed at it, which is the strongest argument available for pursuing a paediatric label. If Novo Nordisk or Eli Lilly wins one, the addressable population expands into a group that stays on treatment for years rather than months. That is a genuine expansion, not a rounding error. But volume that arrives ahead of a label is also the kind that regulators, payers and journalists revisit later, and rarely at a convenient moment. A payer looking to cut costs finds off-label paediatric prescribing an easy first target. The same curve supports a bull case and a coverage restriction.
The part nobody can price is what happens over time. There is no long-term safety data for GLP-1 receptor agonists started at age nine, because there has not yet been enough time to collect any. The open questions are specific rather than vague: what sustained appetite suppression does during the years of fastest growth and bone accrual, what happens to muscle mass in a body that is still building it, and what occurs when a child stops. The study's lead investigator said plainly that long-term safety monitoring is needed to ensure the drugs remain safe and effective. That is not a warning that something has gone wrong. It is an acknowledgement that the evidence base is behind the prescribing, and will stay behind for years.
We are tracking this because it is the kind of change that does not announce itself. There was no company press release, no regulatory decision and no trial readout. A prescribing pattern shifted quietly over seven years and was then measured, and the measurement is what turns it into news. Whether a paediatric label follows, and whether payers tolerate the use before one arrives, will do more to the numbers at Novo Nordisk over the next five years than most of the trial results the market watches week to week. Disclosure: the author holds shares in Novo Nordisk and Eli Lilly; the full statement is on the About page. This is general information, not medical advice.